SBIR/STTR Research Award

ADF, novel cytokine PPAR-gamma regulator from fat cells

Award identifier 33bba22ef9605a9b7508cd69e4c44e76ee41c32919d87a206c450fd680c39f0dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

STTR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
GENETEX, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Scanned from the Applicant's Abstract): Obesity is a major risk factor for diabetes mellitus (type 2; NIDDM). Fat cells secrete both diabetes promoting molecules (fatty acids; TNF-alpha) and at least one molecule that may be antidiabetic (leptin). We have partially purified a new protein (cytokine) which is also secreted by mature adipocytes, Adipocyte Differentiation Factor (ADF). We hypothesize that ADF may have antidiabetic action, since, like the antidiabetic thiazolidinedione drugs, it induces fat cell differentiation and is a positive regulator for genes involved in the control of adipose cell proliferation and glucose metabolism. One of these genes is the nuclear transcription factor PPAR-gamma. This important regulator of adipose cell differentiation is now increasingly recognized as involved in numerous metabolic pathways and neoplasms. PPAR-gamma is activated in vivo and in culture by the thiazolidinedione class of drugs, now widely used as therapeutic agents in diabetes and experimentally in certain human cancers. However, the physiologic regulation of PPAR-gamma itself is not understood. ADF initiates very rapid fat cell differentiation and increases PPAR-gamma mRNA and protein levels. The purification of ADF will permit the development of assays for use in understanding the physiology of ADF and to develop treatments for obesity, diabetes, and other diseases in which PPAR-gamma proves to play a key role. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.